Compare KSPI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KSPI | GMAB |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | Kazakhstan | Denmark |
| Employees | N/A | 3088 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 16.2B |
| IPO Year | 2023 | N/A |
| Metric | KSPI | GMAB |
|---|---|---|
| Price | $89.76 | $25.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $104.33 | $39.56 |
| AVG Volume (30 Days) | 535.8K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.90 | $17.85 |
| Revenue Next Year | $16.80 | $16.04 |
| P/E Ratio | $7.12 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $68.59 | $20.23 |
| 52 Week High | $99.11 | $35.43 |
| Indicator | KSPI | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 39.44 |
| Support Level | $71.17 | $25.34 |
| Resistance Level | $93.59 | $29.64 |
| Average True Range (ATR) | 3.02 | 0.71 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 88.11 | 10.88 |
Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform, which derives maximum revenue, connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.